Incidence and Features of Lymphoid Proliferation and Lymphomas after Solid Organ or Hematopoietic Stem Cell Transplantation in a National Database Cohort
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Post-transplantation lymphoproliferative disorders (PTLDs) after hematopoietic stem transplantation (HCT) or solid organ transplantation (SOT) result in poorer outcomes, including death. There are limited large cohort data on the incidence and natural course of PTLD in Asians.Materials and Methods We investigated PTLD using Korean national health insurance claims data of 47,518 patients who underwent HCT or SOT in 2008-2020. Patient demographics, time and type of PTLD diagnosis, type of PTLD treatment, and death data were collected. We used Fine and Gray subdistribution hazard models to calculate the cumulative incidence and risk factors for PTLD.Results During median follow-up of 5.32 years, PTLD occurred in 294 of 36,945 SOT patients (0.79%) and 235 of 10,573 HCT patients (2.22%). Cumulative incidence of PTLD were 0.49% at 1 year, 1.02% at 5 years, and 1.50% at 10 years post-transplantation. Age < 20 years (subdistribution hazard ratio [SHR] of 1.67 in age 10-19, SHR 1.51 in age 0-9), HCT (SHR 3.02), heart transplantation (SHR 2.27), and liver transplantation (SHR 1.47) were significant risk factors for PTLD. The presence of PTLD was associated with an increased risk of death (hazard ratio of 2.84). Overall, 5-year survival of PTLD patients was 68.9% (95% confidence interval, 64.9 to 73.2).Conclusion We observed a steady increase in PTLD over 10 years after HCT or SOT in this large cohort study. Pediatric age group, HCT, liver transplantation, and heart transplantation were suggested to be risk factors for PTLD, and PTLD was associated with a higher risk of death.
Abstract
Purpose Post-transplantation lymphoproliferative disorders (PTLDs) after hematopoietic stem transplantation (HCT) or solid organ transplantation (SOT) result in poorer outcomes, including death. There are limited large cohort data on the incidence and natural course of PTLD in Asians.Materials and Methods We investigated PTLD using Korean national health insurance claims data of 47,518 patients who underwent HCT or SOT in 2008-2020. Patient demographics, time and type of PTLD diagnosis, type of PTLD treatment, and death data were collected. We used Fine and Gray subdistribution hazard models to calculate the cumulative incidence and risk factors for PTLD.Results During median follow-up of 5.32 years, PTLD occurred in 294 of 36,945 SOT patients (0.79%) and 235 of 10,573 HCT patients (2.22%). Cumulative incidence of PTLD were 0.49% at 1 year, 1.02% at 5 years, and 1.50% at 10 years post-transplantation. Age < 20 years (subdistribution hazard ratio [SHR] of 1.67 in age 10-19, SHR 1.51 in age 0-9), HCT (SHR 3.02), heart transplantation (SHR 2.27), and liver transplantation (SHR 1.47) were significant risk factors for PTLD. The presence of PTLD was associated with an increased risk of death (hazard ratio of 2.84). Overall, 5-year survival of PTLD patients was 68.9% (95% confidence interval, 64.9 to 73.2).Conclusion We observed a steady increase in PTLD over 10 years after HCT or SOT in this large cohort study. Pediatric age group, HCT, liver transplantation, and heart transplantation were suggested to be risk factors for PTLD, and PTLD was associated with a higher risk of death.
참고문헌 (29)
- Singavi AK, "Post-transplant lym phoproliferative disorders", Cancer Treat Res, 165, pp.305~327 (2015)
- Dharnidharka VR, "Post-transplant lymphoproliferative disorders", Nat Rev Dis Primers, 2, pp.15088~ (2016)
- Alaggio R, "The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours : Lymphoid Neoplasms", Leukemia, 36, pp.1720~1748 (2022)
- Luskin MR, "The impact of EBV status on characteristics and out comes of posttransplantation lymphoproliferative disorder", Am J Transplant, 15, pp.2665~2673 (2015)
- Enok Bonong PR, "Factors associated with post-transplant active Epstein-Barr virus infection and lymphoproliferative disease in hematopoietic stem cell transplant recipients : a sys tematic review and meta-analysis", Vaccines(Basel), 9, pp.288~ (2021)
- Poeschel V, "Four versus six cycles of CHOP chemo therapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis(FLYER) : a randomised, phase 3, non-inferiority trial", Lancet, 394, pp.2271~2281 (2019)
- Allen UD, "Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ trans plantation : guidelines from the American Society of Trans plantation Infectious Diseases Community of Practice", Clin Transplant, 33, pp.e13652~ (2019)
- Chan TS, "Post-transplant lymphoproliferative diseases in Asian solid organ transplant recipients : late onset and favorable response to treatment", Clin Transplant, 26, pp.679~683 (2012)
- Seo E, "Epstein-Barr viral load monitoring for diagnosing post-transplant lym phoproliferative disorder in pediatric liver transplant recipi ents", Pediatr Transplant, 24, pp.e13666~ (2020)
- Liu Y, "Post transplant lymphoproliferative disorder after paediatric liver transplantation", Int J Clin Pract, 75, pp.e13843~ (2021)
- Fujimoto A, "Risk factors and predictive scoring system for post-transplant lymphoproliferative disorder after hemat opoietic stem cell transplantation", Biol Blood Marrow Trans plant, 25, pp.1441~1449 (2019)
- Kim JA, "Towards actualizing the val ue potential of Korea Health Insurance Review and Assess ment(HIRA)data as a resource for health research : strengths, limitations, applications, and strategies for optimal use of HIRA Data", J Korean Med Sci, 32, pp.718~728 (2017)
- Fine JP, "A proportional hazards model for the sub distribution of a competing risk", J Am Stat Assoc, 94, pp.496509~ (1999)
- Curtis RE, "Risk of lymphoproliferative disorders after bone marrow transplantation : a multi-institutional study", Blood, 94, pp.2208~2216 (1999)
- Landgren O, "Risk factors for lymphoproliferative dis orders after allogeneic hematopoietic cell transplantation", Blood, 113, pp.4992~5001 (2009)
- Styczynski J, "Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphopro liferative disorder after hematopoietic stem cell transplant in children and adults : a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation", Clin Infect Dis, 57, pp.794~802 (2013)
- Sundin M, "The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allo geneic hematopoietic stem cell transplantation", Haematolog ica, 91, pp.1059~1067 (2006)
- Pegoraro F, "Post-transplantation lymphoproliferative disorder after haematopoietic stem cell transplantation", Ann Hematol, 100, pp.865~878 (2021)
- Santarsieri A, "Incidence and outcomes of post-transplant lymphopro liferative disease after 5365 solid-organ transplants over a 20year period at two UK transplant centres", Br J Haematol, 197, pp.310~319 (2022)
- Kasiske BL, "Lymphoproliferative disorders after adult kidney trans plant : epidemiology and comparison of registry report with claims-based diagnoses", Am J Kidney Dis, 58, pp.971~980 (2011)
- Francis A, "Incidence and predictors of post-transplant lymphoprolifera tive disease after kidney transplantation during adulthood and childhood : a registry study", Nephrol Dial Transplant, 33, pp.881~889 (2018)
- Sprangers B, "Posttransplant lymphopro liferative disorder following kidney transplantation : a review", Am J Kidney Dis, 78, pp.272~281 (2021)
- Caillard S, "Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients : report of the French registry and analysis of subgroups of lymphomas", Am J Transplant, 12, pp.682~693 (2012)
- Narkewicz MR, "Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoprolif erative disorder in pediatric liver transplant recipients : report of the studies of pediatric liver transplantation experience", Liver Transpl, 19, pp.730~740 (2013)
- Opelz G, "Lymphomas after solid organ transplanta tion : a collaborative transplant study report", Am J Transplant, 4, pp.222~230 (2004)
- Engels EA, "Spectrum of cancer risk among US solid organ transplant recipients", JAMA, 306, pp.1891~1901 (2011)
- Kitchlu A, "Elevated risk of cancer after solid organ transplant in childhood : a population-based cohort study", Transplantation, 103, pp.588~596 (2019)
- "Annual report of cancer statistics in Korea in 2019" (2019)[URL]
- Kim SK, "Analysis of the change in seropositive rate of Epstein-Barr virus in Koreans : a single-center study", Pediatr Infect Vaccine, 27, pp.117~126 (2020)